



Received on 05 July, 2010; received in revised form 10 October, 2010; accepted 12 November, 2010

PHYTOCHEMICAL AND PHARMACOLOGICAL ASPECTS OF EUCALYPTUS GENUS

N. Nagpal*¹, G. Shah¹, M. Arora N.¹, R. Shri² and Y. Arya²

B.I.S. College of Pharmacy¹, Gagra, Moga, Punjab, India

Department of Pharmaceutical Sciences and Drug Research, Punjabi University², Patiala, Punjab, India

Keywords:

Eucalyptus,
Phytochemical,
Pharmacological activities

Correspondence to Author:

Navneet Nagpal

B.I.S. College of Pharmacy, Gagra-
142103, Moga, Punjab, India

ABSTRACT

Eucalyptus is a diverse genus of flowering trees and shrubs in the myrtle family, Myrtaceae. Different chemical constituents such as Sideroxyllonal C, (+)-oleuropeic acid, cypellocarpins A, B and C, cypellogins A, B and C, Leptospermone, Isoleptospermone, grandinol, various essential oils and many others have been isolated from plants of eucalyptus genus. Various eucalyptus species have been reported to possess potent pharmacological actions against diabetes, hepatotoxicity, inflammation, cancer etc. This review article is presented to compile all the updated information on phytochemical and pharmacological activities of Eucalyptus species which have been performed by widely different methods.

INTRODUCTION: Eucalyptus is a large genus of evergreen aromatic trees, rarely shrubs (mallees), indigenous to Australia, Tasmania, New Guinea and the neighboring islands, where they constitute a large portion of the forest vegetation and giving it a characteristic appearance. Various species of *Eucalyptus* are cultivated, particularly in sub-tropical and warm temperate regions, on account of their economic value ¹.

Eucalyptus species (Family- Myrtaceae) are remarkable for their rapid growth. Some species of them, in their natural habitat, attain gigantic sizes and are among the tallest trees of the world. Most of the species are popularly called “gum trees” although the exudation from them is not a gum, but an astringent; a tanniferous substance called “kino”.

Major species: There are over 500 species of *Eucalyptus*. *Amygdalina*, *australiana*, *botryoides*, *calophylla*, *camaldulensis*, *citriodora*, *cladocalyx*, *consideniana*, *cypellocarpa*, *dives*, *gigantea*, *globulus*, *gomphocephala*, *grandis*, *gunnii*, *incrassate*, *kino*, *largeflorens*, *lesouefii*, *macrocarpa*, *macrorhyncha*, *maculata*, *marginata*, *melanophloia*, *meliiodora*, *microtheca*, *nitens*, *ovata*, *pauciflora*, *perriniana*, *pilularis*, *polyanthemos*, *polybractea*, *populnea*, *radiata*, *regnans*, *risdonni*, *robusta*, *rossi*, *Ostrata*, *saligna*, *sideroxyton*, *sieberiana*, *smithii*, *tereticornis*, *tetradonta*, *umbra*, *urophylla*, *viminalis*, *wandoo* are the major species of *Eucalyptus* genus.

Taxonomical Classification:

Kingdom	:	Plantae
Subkingdom	:	Tracheobionta
Super division	:	Spermatophyta
Division	:	Magnoliophyta
Class	:	Magnoliopsida
Subclass	:	Rosidae
Order	:	Myrtales
Family	:	Myrtaceae
Genus	:	<i>Eucalyptus</i>

PHYTOCHEMICAL AND PHARMACOLOGICAL ASPECTS:

1. *Eucalyptus albens*:

Chemical Constituents: Sideroxytonal C, isolated from the flowers of *Eucalyptus albens* is the major chemical constituent of *E. albens*.

Pharmacological Activity: Sideroxytonal C inhibits human plasminogen activator inhibitor type-1 without any significant effect on human tissue plasminogen activator ².

2. *Eucalyptus amplifolia*

Chemical Constituents: Euglobal-Am-II, Euglobal-Am-IVb and Euglobal-Am-VII (acylphloroglucinol-monoterpenes) are the main chemical constituent.

Pharmacological Activity: Euglobal-Am-II isolated from leaves of *Eucalyptus amplifolia*, exhibit significant inhibitory effects on Epstein-Barr virus (EBV) ³.

3. *Eucalyptus camaldulensis*:

Chemical Constituents: Essential oil (Aromandendrene Myrtenal, Borneol, Camphene, Carvacrol Citronellal Citronellyl acetate, Cryptone- α - Terpenyl acetate.) ⁴, Flavonoids (Apigenin, Chrysin, Flavone, Luteolin, Eriodictyol, Hesperetin, Naringenin, Pinocembrin), ⁵ Triterpenoids (Oleanolic Acid, Maslinic Acid, Camaldulic Acid, Camaldulenic Acid) are the main constituents present in *E. camaldulensis* ⁶⁻¹⁰.

Pharmacological Activity:

Antimicrobial: Bark of *Eucalyptus camaldulensis* is commonly used as a chewing stick. Bark extract of *Eucalyptus camaldulensis* shows inhibition zones of comparable magnitude with those of the standard antimicrobial agents ¹¹.

Anti-Nociceptive: *Eucalyptus camaldulensis*, possesses an anti-nociceptive effect against both acetic acid-induced writhing and hot plate-induced thermal stimulation¹².

Antioxidative: The extracts obtained by ethanol digestion and by supercritical fluid extraction (SFE; CO₂ with 15% ethanol) of leaves from *Eucalyptus camaldulensis* var. *brevirostris* trees show the most promising antioxidative activities. The main two compounds of the SFE extract with antioxidative activity are 5-hydroxy-7, 4'-dimethoxy flavone and 5-hydroxy-7, 4'-dimethoxy-8-methyl flavone. Gallic and ellagic acid are found to be the prevailing antioxidants in the ethanolic extract¹³.

Cytotoxic: Extracts obtained from *Eucalyptus camaldulensis* has significant cytotoxic activity against human ECV-304 cells¹⁴.

4. *Eucalyptus citriodora*:

Chemical Constituents: Essential oils (Cineole, Citronellal, Citronellic Acid)¹⁵, Sterols (9 β -Sitosterol) are mainly present in this species¹⁶.

Pharmacological Activity:

Analgesic: Using acetic acid-induced writhes in mice and hot plate thermal stimulation in rats, it has been proved that the essential oil of *Eucalyptus citriodora* induced analgesic effects in both models, suggesting peripheral and central actions.

Antifungal activity: The volatile oil extracted from the leaves of *Eucalyptus citriodora* showed a wide spectrum of antifungal activity. *Eucalyptus* oil, camphor and menthol and thymol oil are the most efficacious component against the fungal pathogens such as *Tricophyton rubru*,, *Trichophyton mentagrophytes*, *Microsporum canis*, *Epidermophyton floccosum* and *Epidermophyton stockdale*¹⁷.

Anti-inflammatory: Essential oil from the *Eucalyptus citriodora* produced anti-inflammatory effects, Anti inflammatory activity of *Eucalyptus citriodora* demonstrated by inhibition of rat paw edema induced by carrageenan and dextran, neutrophil migration into rat peritoneal cavities induced by carrageenan, and vascular permeability induced by carrageenan and histamine.

Bone Resorption Inhibition: *Eucalyptus* essential oil and monoterpenes are efficient inhibitors of bone resorption in the rat¹⁸.

Natural repellent: A lemon *Eucalyptus* extract (Citriodiol) has been shown to be a natural repellent against mosquitoes, stable flies, and midges^[19]. It kill the *Ixodes ricinus* which can transmit several microorganisms, out of which *Borrelia burgdorferi* and tick-borne encephalitis (TBE) virus are the most important pathogens in humans.

5. *Eucalyptus cladocalyx*:

Chemical Constituents: triterpene named cladocalol isolated from the leaves, ursulolactone acetate, ursolic acid, 3- beta- acetate-12, 20 (29)-lupadien- 28- oic acid, beta- sitosterol and eucalyptine are the major chemical constituents of this species²⁰.

Pharmacological Activity: Cladocalol and its derivatives induce cytotoxic effect on the myeloid leukemia cell line HL-60.

6. *Eucalyptus cypellocarpa*:

Chemical Constituents: Acylated flavonol glycosides, cypellogins A, B and C are the major chemical constituents, present in leaves of *Eucalyptus cypellocarpa*²¹.

Pharmacological Activity: Cypellogins A, B and C showed potent in vitro antitumor-promoting

activity. These compounds also suppressed an in vivo two-stage carcinogenesis induced with nitric oxide and TPA (12- O- tetradecanoyl phorbol 13- acetate) on mouse skin²².

7. *Eucalyptus globules*:

Chemical Constituents: Euglobals, Essential oil (1, 8-Cineole, Carvone, Citral, Citronellal, Geranyl acetate, α -Pinene, α -Pinocarvone, β -Pinene)²³⁻²⁵ Hydrocarbons (4-Hydroxytritriacontane-16, 18-dione, 16-Hydroxy Btritriacontanone, n-Tritriacontane 16, 18-dione), Macrocarpals H, I, J²⁶ are main chemical constituents.

Pharmacological Activity:

Antibacterial: A 50% EtOH extract of *Eucalyptus globulus* leaves have antibacterial activity against oral pathogenic microorganisms with MIC values ranging from 0.20 micrograms/mL to 6.25 micrograms/mL. A 50% EtOH-soluble material was extracted from the dried leaves of *E. globules* shows appreciable antibacterial activity against *S. mutans* Ingbritt and *P. gingivalis* ATCC 33277 (causes dental caries and periodontal disorders) with MICs values 12.5 and 6.25 μ g/ml²⁷.

Dried residue of methalonic extract of *Eucalyptus globulus* leaves showed antimicrobial activity against *Staphylococcus aureus*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Candida albicans* with minimum inhibitory concentration of 5.0, 10.0, 10.0, 1.25 mg/ml respectively²⁸. Phloroglucinol- sesquiterpene coupled compounds, macrocarpals H, I, and J showed potent antibacterial activity and inhibitory effect of glucosyltransferase²⁹. Ethanolic extract of *Eucalyptus globulus* also active against the reference strains of *Staphylococcus aureus*, *Saturia hortensis* L., *Teucrium polium* L³⁰. Most concentrations of the extracts of the *Eucalyptus globulus* showed a high antibacterial activity against *Pseudomonas aerugenosa*³¹.

Methanol-dichloromethane extract of *Eucalyptus globulus*, significantly inhibited the growth of six Gram-positive bacteria (*Staphylococcus aureus*, MRSA, *Bacillus cereus*, *Enterococcus faecalis*, *Alicyclobacillus acidoterrestris*, *Propionibacterium acnes*), and a fungus (*Trichophyton mentagrophytes*). Periodontopathic bacterial strains tested were killed completely by exposure for 30 seconds to 0.2% oil of *Eucalyptus globules*³². The antibacterial activity of *Eucalyptus globulus* leaf extract has been determined against *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae* and *Haemophilus influenzae* obtained from 200 clinical specimens of patients with respiratory tract disorders³³.

Antidiabetic: *Eucalyptus globulus* is used as a traditional treatment for diabetes. Incorporation of *Eucalyptus globulus* in the diet (62.5 g/kg) and drinking water (2.5 g/L) reduced the hyperglycemia and associated weight loss of streptozotocin-treated mice. An aqueous extract of *Eucalyptus globolus* (AEE) (0.5 g/L) enhanced 2-deoxy-glucose transport by 50%, glucose oxidation by 60% and incorporation of glucose into glycogen by 90% in abdominal muscle of mice. In acute, 20 min incubation, 0.25-0.5 g AEE/L evoked a stepwise 70-160% enhancement of insulin secretion from the clonal pancreatic beta-cell line (BRIN-BD11). These data indicate that *Eucalyptus globulus* represents an effective antihyperglycemic dietary adjunct for the treatment of diabetes and a potential source for discovery of new orally active agent(s) for future therapy³⁴.

Antiplaque: *Eucalyptus globulus* may be useful in inhibiting dental plaque formation³⁵.

Antitumor: Antitumor-promoting activity of Euglobals Ia₁, Ia₂, Ib, Ic, IIa, IIb, IIc, III, IVa, IVb, and V and VIII has been tested *in vitro* on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced Epstein-Barr virus early antigen (EBV-EA)

activation test system. Euglobal-III showed strong inhibitory activity, followed by euglobals Ib, IIa, Ic, Ia1, Ia2³⁶. *Eucalyptus globulus* oil inhibits the nuclear translocation of NF-kappa B induced by LPS in THP-1 cells³⁷.

Antiviral: Twelve euglobals from *Eucalyptus globulus* and their twenty-six related compounds were examined for their inhibitory effects on Epstein-Barr virus activation by a short-term in vitro assay. The results showed that most of the euglobals having monoterpene structures, and euglobal-III had strong inhibitory activity³⁸. *Eucalyptus globulus* oil has antiviral activity against herpes simplex virus (herpes simplex virus-1 and -2)³⁹.

Antifungal: Freshly prepared camphor oil from *Eucalyptus globulus* with or without glycerol dilutions gave complete cure of human facial demodicidosis with concentrations of 100%, 75% and 50%⁴⁰. *Eucalyptus globulus* leaf extracts and oil showed antifungal property as they progressively inhibited the growth of *Malassezia furfur* on Sabouraud's destrose agar medium⁴¹.

Antihistaminic: Hexane extract of leaves, ethanol extract of fruits and leaves of *Eucalyptus globulus* inhibited IgE dependent histamine release from RBL-2H3 cells⁴².

Anti-inflammatory: 1,8-cineole, major constituent present in volatile oil of *Eucalyptus globulus* is a strong inhibitor of cytokines, that might be suitable for long term treatment of airway inflammation in bronchial asthma and other steroid-sensitive disorders⁴³. Using acetic acid-induced writhes in mice and hot plate thermal stimulation in rats, it has proved that the essential oil of *Eucalyptus globulus* induced analgesic effects in both models, suggesting peripheral and central actions. In addition, essential oil extracts from the *Eucalyptus globulus* produced anti-inflammatory effects, as demonstrated by

inhibition of rat paw edema induced by carrageenan and dextran, neutrophil migration into rat peritoneal cavities induced by carrageenan, and vascular permeability induced by carrageenan and histamine⁴⁴.

E. globulus oil has the anti-inflammatory effect on chronic bronchitis induced by lipopolysaccharide in rats and the inhibition effect on hypersecretion of airway mucins⁴⁵. *E. globulus* extracts significantly inhibited the enhanced production of NO induced by LPS and IFN-gamma in a dose-dependent manner. It is well known that nitric oxide (NO) plays an important role in the pathogenesis of inflammatory diseases. *Eucalyptus globulus* have been used in traditional medicine in the treatment of bronchitis, asthma and other respiratory diseases⁴⁶.

Cutaneous application of essential oils of *Eucalyptus globulus* to mice suppressed the cellular inflammation of skin. This suggests that essential oils using in aromatherapy massage may suppresses the inflammatory symptoms related with neutrophil accumulation and edema⁴⁷.

Antimalarial: *Eucalyptus globulus* oil significant action against plasmodium species. It is popularly used anti-malarial plants in Brazil⁴⁸.

Antioxidant: The methanol extracts of *Eucalyptus globulus* showed efficiency in preventing the oxidation process.

Cytochrome p450 enzymes inhibitor: *Eucalyptus* oil (*Eucalyptus globulus*), is identified as inhibitor of the six major cytochrome P450 enzymes with IC(50) values between 20 and 1000 µg/MI⁴⁹.

Intestinal Fructose Absorption Inhibition: *Eucalyptus globulus* leaf extract inhibits intestinal fructose absorption, and suppresses adiposity due to dietary sucrose in rats⁵⁰.

Larvicidal: *Eucalyptus globulus* leaves has potent action against *Culex quinquefasciatus* and *Culex tritaeniorhynchus*⁵¹.

Nerve Blocker: Terpeneol, a relatively nontoxic, volatile monoterpene alcohol, is a major component of the essential oil of *Eucalyptus globulus* (*Eucalyptus*), is widely used in folk medicine and aromatherapy. Terpeneol induced a dose-dependent blockade of the compound action potential (CAP) of rat sciatic nerve⁵².

8. *Eucalyptus grandis*:

Chemical Constituents: Volatile oil from *E. grandis* contains cyclic ketones i.e. Flavesone, Leptospermone, Isoleptospermone, grandinol⁵³, euglobals G8–G12, together with a known euglobal-IIc present in leaves of *Eucalyptus grandis*⁵⁴. Other volatile oils present in *E. grandis* are α -pinene (44.7%), camphene (0.8%), β -pinene (30.5%), limonene (5.6%), β -phellandrene (0.2%), 1,8-cineole (2.7%), γ -terpinene (0.3%), terpinolene (0.8%), α -fenchyl alcohol (0.6%), terpinen-4-ol (0.9%) and α -terpeneol (5.4%)

Pharmacological Activity:

Anticancer: Euglobal-G1 (EG-1) is an active constituent, inhibited the promotion stages on two-stage carcinogenesis induced by both TPA-type and non TPA-type promoter (fumonisin B1). It inhibited the pulmonary tumor genesis induced by 4-NQO and glycerol. Therefore, EG-1 might be valuable as a chemo protective agent in chemical carcinogenesis.

Antiviral: Euglobal- G1, -G2, and -G3 strongly inhibited the Epstein-Barr virus activation⁵⁵. Euglobal-G1–G5 isolated from leaves of *Eucalyptus grandis* exhibited significant inhibitory effects on Epstein-Barr virus (EBV) activation induced by TPA.

9. *Eucalyptus macrocarpa*:

Chemical Constituents: Phloroglucinol dialdehyde diterpene derivatives (macrocarpals B, C, D, E, F, G) are the main constituents of leaves of *Eucalyptus macrocarpa*⁵⁶.

Pharmacological Activity: macrocarpals A, B, D, and G have inhibitory activity against porcine lens ALR2 (Aldose reductase)⁵⁷.

10. *Eucalyptus occidentalis*:

Chemical Constituents: 6, 8- di- C-methylkaempferol 3, 4'- dimethyl ether, 6, 8- di-C-methylkaempferol 3- methyl ether, oleanolic acid, and 2 α , 3 β dihydroxyurs- 12- en- 28- oic acid are the main constituents present in aerial parts of *Eucalyptus occidentalis*.

Pharmacological Activity: Flavonoids (6, 8-di-C-methylkaempferol 3, 4'-dimethyl ether and 6, 8-di-C-methylkaempferol 3-methyl ether) have been used for study the biological activities of the human promyelocytic leukemia cell line, HL-60. These compounds induce morphological changes and inter nucleosomal DNA fragmentation characteristic of apoptotic cell death, which is mediated by caspase-8/caspase-3 activation and cytochrome c release⁵⁸.

11. *Eucalyptus radiata*

Chemical Constituents: 1, 8-cineole (74.2%) followed by alpha-terpeneol (11.6%) and limonene (4.5%) are the major component of essential oil of *Eucalyptus radiata*⁵⁹.

Pharmacological Activity: Volatile oil is effective against 20 species of *Listeria monocytogenes*⁶⁰.

12. *Eucalyptus robusta*:

Chemical Constituents: Robustadial A and B are the major constituents of *Eucalyptus robusta* leaves⁶¹.

Pharmacological Activity: Decoction of the leaves and bark is used to treat fever and to wash skin diseases ⁶². Leaves are used in China for the treatment of dysentery, malaria and bacterial diseases ⁶³.

13. *Eucalyptus viminalis*:

Chemical Constituents: Euvimal-1 and euvimal-2 are the main constituents of leaf of *Eucalyptus viminalis*.

Pharmacological Activity:

Antibacterial: Methanol-Dichloromethane extract of *Eucalyptus viminalis* leaves significantly inhibited the growth of six Gram-positive bacteria (*Staphylococcus aureus*, MRSA, *Bacillus cereus*, *Enterococcus faecalis*, *Alicyclobacillus acidoterrestris*, *Propionibacterium acnes*), and of a fungus (*Trichophyton mentagrophytes*), but they did not show strong antibacterial activity against Gram-negative bacteria (*Escherichia coli*, *Pseudomonas putida*) ⁶⁴.

14. *Eucalyptus tereticornis*:

Chemical Constituents: Essential oil (1, 8-Cineole, Camphene, Carvone, Citral, Citronellal, Geranyl acetate, Limonene, Linalool oxide), Phloroglucinol monoterpene derivatives (Euglobal-T1, Euglobal IIc), urosolic acid ⁶⁵ and Triterpene esters (Tereticornate A and B) ⁶⁶ are the main constituents of *E. tereticornis*.

Pharmacological Activity:

Anti-Hyperglycemic: *Eucalyptus tereticornis* exhibited anti-hyperglycemic activities when fed simultaneously with glucose ⁶⁷.

Hepatoprotective: Ursolic acid isolated from the leaves of *Eucalyptus* hybrid *E. tereticornis* showed a dose dependent (5-20 mg/kg) hepatoprotective activity (21-100%) in rats against thioacetamide,

galactosamine and carbon tetrachloride induced hepatotoxicity ⁶⁸.

Myorelaxant: Essential Oil of *Eucalyptus tereticornis* produces myorelaxant effects on guinea-pig isolated trachea ⁶⁹.

CONCLUSION: The extensive survey of literature revealed that *Eucalyptus* species is an important source of many pharmacologically and medicinally important chemicals, such as Essential oils, terpenoids which have been used in aromatherapy. Various *Eucalyptus* species have also been widely studied for their various pharmacological activities like analgesic, antifungal, anti-inflammatory, antibacterial, antidiabetic, antioxidative, Antiviral, Antitumor, antihistaminic, anticancer cytochrome p450 inhibitor and hepatoprotective properties. Although aromatherapy is pleasant, inexpensive, and has little side effects (except for rare allergies), there is little evidence that it is effective in patients undergoing medical interventions.

REFERENCES:

1. Sastri BN: The Wealth of India. A Dictionary of India Raw Materials and Industrial Products. Raw Materials. Vol V. Council of Scientific and Industrial Research. New Delhi: 2002; 203-204.
2. Neve J *et al.*: Sideroxylylonal C: A new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of *Eucalyptus albens*. J. Nat. Prod. 1999; 62: 324-326.
3. Takasaki M, Konoshima T, Kozuka M and Tokuda H: Anti-tumor promoting activities of euglobals from *Eucalyptus* plants. Biol. Pharm. Bull. 1995; 18: 435-438.
4. Cimanga K *et al.*: Correlation between chemical composition and antibacterial activity of essential oils of some aromatic medicinal plants growing in the Democratic Republic of Congo. J. Ethnopharmacol. 2002; 79: 213-220.
5. Cimpan G and Gocan S: Analysis of medicinal plants by HPLC: Recent approaches. J. Liquid Chromatography & Related Technologies. 2002; 25: 2225-2292.
6. Rastogi RP and Mehrotra BN: Compendium of Indian Medicinal Plants. CDRI, Lucknow, Publication and Information Directorate, New Delhi. 1995; 4: 297-300.
7. Begum S and Siddiqui BS: Triterpenoids from the Leaves of *Eucalyptus camaldulensis* var. obtusa. J. Nat. Prod. 1997; 60: 20-23.
8. Begum S *et al.*: Spasmolytic constituents from *Eucalyptus camaldulensis* var. obtusa leaves. J. Nat. Prod. 2000; 63:1265-1268.

9. Siddiqui BS, Sultana I, Begum S: Triterpenoidal constituents from *Eucalyptus camaldulensis* var. obtusa leaves. *Phytochemistry*. 2000; 54: 861-865.
10. Begum S, Sultana I, Siddiqui BS: Structure and spasmolytic activity of eucalyptanoic acid from *Eucalyptus camaldulensis* var. obtusa and synthesis of its active derivative from oleanolic acid. *J. Nat. Prod.* 2002; 65: 1939-1941
11. Khan MN, Ngassapa O, Matee MIN: Antimicrobial Activity of Tanzanian Chewing Sticks against Oral Pathogenic Microbes. *Pharmaceutical Biology*. 2000; 38: 235–240.
12. Atta AH, and Alkofahi A: Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts. *J. Ethnopharmacol.* 1998; 60:117-124.
13. El-Ghorab AH, El-Massry KF, Marx F, Fadel H. M.: Antioxidant activity of Egyptian *Eucalyptus camaldulensis* var. brevirostris leaf extracts. *Nahrung*, 2003; 47: 41-45.
14. Al-Fatimi M, Friedrich U, Jenett-Siems K: Cytotoxicity of plants used in traditional medicine in Yemen. *Fitoterapia*. 2005; 76: 355-358.
15. Low D, Rawal BD, Griffin WJ: Antibacterial action of the essential oils of some Australian Myrtaceae with special references to the activity of chromatographic fractions of oil of *Eucalyptus citriodora*. *Planta Med.* 1974; 26:184-185.
16. Ramezani H, Singh HP, Batish DR and Kohli RK: Antifungal activity of the volatile oil of *Eucalyptus citriodora*. *Fitoterapia*. 2002; 73: 261-262.
17. Ramsewak RS, Nair MG, Stommel M and Selanders L: *In vitro* antagonistic activity of monoterpenes and their mixtures against 'toe nail fungus' pathogens. *Phyther. Res.*, 2003; 17: 376-379.
18. Muhlbauer RC, Lozano A, Palacio S, Reinli A, Felix R: Common herbs, essential oils, and monoterpenes potently modulate bone metabolism. *Bone*. 2003; 32: 372-380.
19. Gardulf A, Wohlfart I, and Gustafson R: A prospective cross-over field trial shows protection of lemon eucalyptus extract against tick bites. *J. Med. Entomol.* 2004; 41: 1064-1067.
20. Benyahia S et al.: Cladocalol: a pentacyclic 28-nor-triterpene from *Eucalyptus cladocalyx* with cytotoxic activity. *Phytochemistry*, 2005; 66: 627-632.
21. Kasajima N, Ito H, Hatano T, Yoshida T, Kaneda M: Cypelloins A, B and C, Acylated Flavonol Glycosides from *Eucalyptus cypellocarpa*. *Chem. Pharm. Bull.* 2005; 53, 1345-1347.
22. Ito H, Koreishi M, Tokuda H, Nishino H, Yoshida T: Cypellocarpins A-C, phenol glycosides esterified with oleuropeic acid, from *Eucalyptus cypellocarpa*. *J. Nat. Prod.* 2000; 63: 1253-1257.
23. Rastogi RP and Mehrotra BN: *Compendium of Indian Medicinal Plants*. CDRI, Lucknow, Publication and Information Directorate, New Delhi.1993; 1:180.
24. Rastogi RP and Mehrotra BN *Compendium of Indian Medicinal Plants*. CDRI, Lucknow, Publications and Information Directorate, New Delhi. 1993; 2:306-307.
25. Dessi M.A. et al. Antioxidant activity of extracts from plants growing in *Sardinia*. *Phyther. Res.* 2001; 15:511-518.
26. Osawa T, Namiki M: Natural Antioxidants Isolated from *Eucalyptus* Leaf Waxes. *J. Agric. Food Chem.* 1985; 33: 777-780.
27. Osawa K, Yasuda H, Morita H, Takeya K Itokawa H: Macrocarpals H, I, and J from the Leaves of *Eucalyptus globulus*. *J. Nat. Prod.* 1996; 59: 823-827.
28. Navarro V, Villarreal ML, Rojas G, Lozoya X: Antimicrobial evaluation of some plants used in Mexican traditional medicine for the treatment of infectious diseases. *J. Ethnopharmacol.* 1996; 53: 143-147.
29. Osawa K, Yasuda H, Morita H, Takeya K, Itokawa H: Configurational and conformational analysis of macrocarpals H, I, and J from *Eucalyptus globulus*. *Chem. Pharm. Bull.* 1997; 45: 1216-1217.
30. Mansouri S: Inhibition of *Staphylococcus aureus* mediated by extracts of Iranian plants. *Pharmaceutical Biology*. 1999; 37: 375-377.
31. Al-Saimary IE et al.: Effects of some plant extracts and antibiotics on *Pseudomonas aeruginosa* isolated from various burn cases. *Saudi Med. J.* 2002; 23: 802-805.
32. Takarada K, Kimizuka R, Takahashi N, Honma K, Okuda K, Kato TA: comparison of the antibacterial efficacies of essential oils against oral pathogens. *Oral Microbiol. Immunol.* 2004; 19: 61-64.
33. Salari MH, Amine G, Shirazi MH, Hafezi R Mohammadypour M: Antibacterial effects of *Eucalyptus globulus* leaf extract on pathogenic bacteria isolated from specimens of patients with respiratory tract disorders. *Clin. Microbiol. Infect.* 2006; 12: 194-196.
34. Gray AM and Flatt PR: Antihyperglycemic actions of *Eucalyptus globulus* (*Eucalyptus*) are associated with pancreatic and extra-pancreatic effects in mice. *J. Nutr.* 1998; 128:2319-2323.
35. Sato S, Yoshinuma N, Ito K, Tokumoto T, Takiguchi T, Suzuk Y Murai S: The inhibitory effect of funoran and eucalyptus extract-containing chewing gum on plaque formation. *J. Oral Sci.* 1998; 40:115-157.
36. Rastogi RP and Mehrotra BN (eds). *Compendium of Indian Medicinal Plants*. CDRI, Lucknow, National Institute of Science Communication, New Delhi. 1998; 5: 336-343.
37. Zhou JY et. al.: Effect of *Eucalyptus globulus* oil on activation of nuclear factor-kappa B in THP-1 cells. *Zhejiang Da Xue Xue Bao Yi Xue Ban.* 2003; 32: 315-318.
38. Takasaki M et al.: Inhibitors of skin-tumor promotion-VIII. Inhibitory effects of euglobals and their related compounds on Epstein-Barr virus activation. *Chem. Pharm Bull.* 1990; 38: 2737-2739.
39. Schnitzler P, Schon K, Reichling J: Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. *Pharmazie*. 2001; 56: 343-347.
40. Morsy TA, Morsy GH Sanad EMJ: *Eucalyptus globulus* (camphor oil) in the treatment of human demodicidosis. *J. Egypt Soc. Parasitol.* 2002; 32:797-803.
41. Vijayakumar R, Muthukumar C, Kumar T, Saravanamuthu R: Characterization of *Malassezia furfur* and its control by using plant extracts. *Indian J. Dermatol.* 2006; 51: 145-148.
42. Ikawati Z, Wahyuono S, Maeyama K: Screening of several Indonesian medicinal plants for their inhibitory effect on histamine release from RBL-2H3 cells. *J. Ethnopharmacol.* 2001; 75:249-256.

43. Juergens UR, Stober M, Vetter H: Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1,8-cineole) in human blood monocytes in vitro. *Eur. J. Med. Res.* 1998; 3: 508-510.
44. Silva J, Abebe W, Sousa SM, Duarte VG, Machado MI, Matos FJ: Analgesic and anti-inflammatory effects of essential oils of *Eucalyptus*. *J. Ethnopharmacol.* 2003; 89: 277-283.
45. LuX Q, Tang FD, Wang Y, Zhao T, Bian RL: Effect of *Eucalyptus globulus* oil on lipopolysaccharide-induced chronic bronchitis and mucin hypersecretion in rats. *Zhongguo Zhong Yao Za Zh.* 2004; 29: 168-171.
46. Vigo E, Cepeda A, Gualillo O: Perez-Fernandez R. In-vitro anti-inflammatory effect of *Eucalyptus globulus* and *Thymus vulgaris*: nitric oxide inhibition in J774A.1 murine macrophages. *J. Pharm. Pharmacol.* 2004; 56: 257-263.
47. Maruyama N et al.: Suppression of neutrophil accumulation in mice by cutaneous application of geranium essential oil. *J. Inflamm. (Lond).* 2005; 2: 1-11.
48. Njoroge GN and Bussmann RW Diversity and utilization of antimalarial ethnophytotherapeutic remedies among the Kikuyus (Central Kenya). *J. Ethnobiology and Ethnomed.* 2006; 2, DOI: 10.1186/1746-4269-2-8. <http://www.ethnobiomed.com/content/2/1/8>
49. Unger M, Frank A: Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated outline extraction. *Rapid. Commun. Mass. Spectrom.* 2004; 18: 2273-2281.
50. Sugimoto K et al.: *Eucalyptus* leaf extract inhibits intestinal fructose absorption, and suppresses adiposity due to dietary sucrose in rats. *Br. J. Nutr.* 2005; 93: 957-963.
51. Monzon RB, Alvior JP, Luczon LL, Morales AS Mutuc FE: Larvicidal potential of five Philippine plants against *Aedes aegypti* (Linnaeus) and *Culex quinquefasciatus* (Say). *Southeast Asian J. Trop. Med. Public Health.* 1994; 25: 755-759.
52. Moreira MR et al.: Effects of terpineol on the compound action potential of the rat sciatic nerve. *Brazilian Journal of Medical and Biological Research.* 2001; 34: 1337-1340.
53. Ghisalberti EL: Bioactive acylphloroglucinol derivatives from *Eucalyptus* species. *Phytochemistry.* 1996; 41: 7-22.
54. Umehara K, Singh IP, Etoh H, Takasaki M, Konoshima T: Five phloroglucinol-monoterpene adducts from *Eucalyptus grandis*. *Phytochemistry.* 1998; 49:1699-1704.
55. Takasaki M et. al.: Inhibitors of skin-tumor promotion. VIII. Inhibitory effects of euglobals and their related compounds on Epstein-Barr virus activation. *Chem. Pharm. Bull.* 1990; 38: 2737-2739.
56. Yamakoshi Y, Murata M, Shimizu A, Homma S: Isolation and characterization of macrocarpals B-G antibacterial compounds from *Eucalyptus macrocarpa*. *Biosci Biotechnol Biochem.* 1992; 56: 1570-1576.
57. Fuente JÁ, Manzanaro S: Aldose reductase inhibitors from natural sources. *Natural Product Reports.* 2003; 20: 243-251.
58. Benyahia S. et al.: Isolation from *Eucalyptus occidentalis* and Identification of a New Kaempferol Derivative that Induces Apoptosis in Human Myeloid Leukemia Cells. *J. Nat. Prod.* 2004; 67: 527-531.
59. Singh AK: Chemical Composition of the Leaf Oil of *Eucalyptus radiata* Sieb. ex DC subsp. *robertsonii* (Blakely) L. Johnson et D. Blaxell: A Rich Source of *Eucalyptus* Oil of Pharmacopoeia Grade. *J. Essent. Oil Res.* 1994; 6: 657-659.
60. Lis-Balchin M, Jeans SG: Bioactivity of selected plant essential oils against *Listeria monocytogenes*. *J. App. Microbio.* 1997; 82: 759-762.
61. Xu R, Snyder JK, Nakanishi K: Robustadiols A and B from *Eucalyptus robusta*. *J. Am. Chem. Soc.* 1994; 106: 734-736.
62. Gurib-Fakim A, Sewraj MD, Gueho J, Dulloo E: Medicinal Plants of Rodrigues. *International Journal of Pharmacognosy,* 1996; 34: 2-14.
63. Schwikkard S, Heerden FR: Antimalarial activity of plant metabolites. *Natural Product Reports* (2002). DOI: 10.1039/b008980j. www.rsc.org/delivery/ArticleLinking/DisplayArticleForFree.cfm?doi=b008980j
64. Spiridonov NA, Arkhipov VV, Foigel AG, Shipulina LD, Fomkina MG: Protonophoric and uncoupling activity of royleanones from *Salvia officinalis* and *euvimals* from *Eucalyptus viminalis*. *Phytother. Res.* 2003; 17: 1228-1230.
65. Kokumai M, Onoshimam T, Ozuka U, Haruna M: Ito K. Euglobal T-1, a new euglobal from *Eucalyptus tereticornis*. *J. Nat. Prod.* 1991; 54: 1082-1086.
66. Wang H, Fujimoto Y: Triterpene esters from *Eucalyptus tereticornis*. *Phytochemistry.* 1993; 33: 151-153.
67. Villasenor IM, Lamadrid MR: Comparative anti-hyperglycemic potentials of medicinal plants. *J. Ethnopharmacol.* 2006; 104: 129-131.
68. Saraswat B, Visen PK, and Agarwal DP: Ursolic acid isolated from *Eucalyptus tereticornis* protects against ethanol toxicity in isolated rat hepatocytes. *Phytother. Res.* 2000; 14: 163-166.
69. Coelho-de-Souza LN et al.: Relaxant effects of the essential oil of *Eucalyptus tereticornis* and its main constituent 1, 8-cineole on guinea-pig tracheal smooth muscle. *Planta Med.* 2005; 71: 1173-1175.
